NIVD World

What NIVD World does

NIVD World is a privately held biotech research and development company building a nanosensor-based in vitro diagnostics (IVD) platform intended to detect infectious diseases, autoimmune conditions, and oncology targets in seconds without the need for laboratory infrastructure. The legal entity is UK NIVD Ltd, registered in England (company number 13728148) with headquarters at 85 Great Portland Street, London; an R&D and science operations site sits inside the Parc Científic de Barcelona at C/Baldiri Reixac, 4-15, 08028. The platform is positioned around four functional claims — low cost, lab-free operation, high accuracy and sensitivity, and real-time readout — with downstream benefits pitched as point-of-care, self-testing, long shelf life, and no storage requirements. Stated use cases span early disease detection, precision medicine, point-of-care diagnostics, and self-testing, aimed at healthcare providers, hospitals, clinics, and patients.

The leadership team comprises Founder/Director Dr Sonia Trigueros, Co-Founder Xavier Anglada, and a Commercial and Operations lead (James Perry, who also serves as Data Protection Officer), supported by an advisory bench covering IP Portfolio (Simon Rendell) and Financial matters (Onesimo Alvarez Moro). The company is GDPR-compliant under UK law with ICO membership reference ZB341533. No products are commercially launched, no customers or distribution partners are named, pricing is not publicly disclosed, and no external funding rounds, institutional investors, patents, or regulatory clearances (CE-mark/FDA) are evidenced in the source material. The careers page lists Administrative and Lab Scientific openings, suggesting the team is small and still being built out. In short, NIVD World is a pre-commercial, founder-led R&D-stage diagnostics platform whose value today rests almost entirely on its underlying nanosensor technology and on the clinical-validation milestones that have not yet been disclosed.

Name

NIVD World

Legal name

UK NIVD Ltd

Website

https://nivd.world

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

NIVD World is a biotech R&D company developing nanosensor-based in vitro diagnostic devices for rapid, lab-free detection of infectious diseases, autoimmune conditions, and oncology targets, serving healthcare providers and patients. Founded 2022; HQ London, R&D Barcelona.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Nanotechnology (541713), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

Keywords

• Nano in vitro diagnostics
• Nanosensor diagnostic devices
• Point-of-care diagnostics
• Rapid disease detection
• Infectious disease diagnostics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Core offering

NIVD World develops and manufactures nano in vitro diagnostic devices (nanosensors) capable of detecting diseases almost instantly in seconds without laboratory infrastructure. The company's main products target infectious diseases, autoimmune conditions, and oncology applications, supporting early disease detection, precision medicine, point-of-care deployment, and patient self-testing.

Product overview

NIVD World offers a unified nano in vitro diagnostics platform centered on nanosensor technology for early disease detection. The core product consists of nanosensors that detect diseases almost instantly (in seconds) and are focused on infectious diseases, autoimmune conditions, and oncology. The solution is characterized as low cost, lab-free, with high accuracy and sensitivity, providing real-time readout. It enables point-of-care and self-testing applications with long shelf life and no storage requirements.

Differentiator

Problem solved

Functional benefit

Products and services

• Nano In Vitro Diagnostics (Nanosensors) Nanosensor-based in vitro diagnostic devices capable of detecting infectious diseases, autoimmune conditions, and oncology markers almost instantly in seconds without laboratory equipment. Designed for healthcare providers, hospitals, clinics, and patient self-testing, with lab-free operation, high accuracy and sensitivity, real-time readout, long shelf life, and no storage requirements.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Cepheid (Danaher): Maker of the GeneXpert system, the dominant rapid molecular point-of-care platform across infectious disease, oncology, and autoimmune-adjacent indications. Directly comparable to NIVD on rapid molecular IVD at POC.
• bioMérieux (BioFire): BioFire FilmArray syndromic panels are the reference point for rapid multiplex molecular diagnostics at POC. Comparable to NIVD on multi-disease panel ambition and speed-to-result claims.
• GenMark Diagnostics (Roche): ePlex platform delivers rapid molecular results for respiratory and bloodstream infections. Directly comparable on rapid molecular POCT workflow and clinical validation burden.

Broad incumbents

• Abbott: Owner of ID NOW, Binax, and Alinity — broad incumbent in rapid and central-lab IVD with global commercial reach. The most directly comparable reference for scale, regulatory posture, and POC market dynamics.
• Roche Diagnostics: Largest IVD manufacturer globally with broad central-lab and POC portfolios. Relevant incumbent peer for benchmarking commercialization, reimbursement, and validation requirements NIVD will face.

Emerging players

• QuantuMDx: UK-based developer of the Q-POC rapid molecular POC device for infectious disease. Closest geographic and stage-comparable peer to NIVD's UK/Spain footprint and nanosensor-style differentiation.
• Oxford Nanopore Technologies: Nanopore-based sequencing platform expanding into rapid infectious-disease diagnostics. Comparable on the nano-enabled diagnostic technology axis and ambition to displace central-lab workflows.
• T2 Biosystems: Developer of T2 Magnetic Resonance-based direct-from-sample diagnostics for sepsis and bloodstream infections. Comparable as a non-PCR, novel-method molecular POC platform pursuing rapid infectious-disease claims.
• Fluxergy: Developer of a sample-to-answer PCR POC platform targeting infectious disease at low cost. Comparable stage and design intent to NIVD's low-cost, lab-free POC positioning.

Regional players

• MGI Tech: Asia-headquartered developer of sequencing and automated molecular diagnostic platforms with a strong LMIC push. Comparable on decentralized, low-cost diagnostic ambitions and platform breadth.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NIVD World